Study: NCT01951053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.